Pricing Log in Create free account

Alnylam Pharmaceuticals, Inc. (ALNY) vs Ascendis Pharma A/S (ASND)

Alnylam Pharmaceuticals, Inc. and Ascendis Pharma A/S are both Biotechnology companies. Alnylam Pharmaceuticals, Inc. is the larger, with a market value of $21.0B against $16.6B — 1.3× the size. Alnylam Pharmaceuticals, Inc. trades at the lower P/E: 7.9× against 18.3×. Ascendis Pharma A/S grew revenue faster over the last twelve months: 126.0% against 56.2%. Ascendis Pharma A/S has the higher net margin (71.2% vs 52.9%) and the lower return on invested capital (15.1% vs 59.4%). Across the 21 metrics below, Alnylam Pharmaceuticals, Inc. leads on 13 and Ascendis Pharma A/S on 8.

Valuation

Metric ALNY ASND Biotechnology median
P/E 7.92 18.30 10.26
P/S 4.19 13.47 9.18
P/B 5.83 9.78 2.05
Price to free cash flow 26.05 42.14 24.81
EV/EBITDA 17.84 49.51 0.65
EV/Sales 3.68 13.12 8.98
Earnings yield 12.62% 5.47% (34.89%)
Free cash flow yield 3.84% 2.37% (24.52%)

Profitability

Metric ALNY ASND Biotechnology median
Gross margin 77.28% 91.26% 65.16%
Operating margin 19.50% 24.84% 0.00%
Net margin 52.85% 71.20% 0.00%
Free cash flow margin 16.08% 31.97% 0.00%
Return on equity 138.07% 118.44% (50.12%)
Return on assets 41.25% 44.34% (45.60%)
Return on invested capital 59.37% 15.07% 0.00%

Growth

Metric ALNY ASND Biotechnology median
Revenue growth (TTM) 56.17% 125.98% 6.26%
EPS growth (last fiscal year) 206.88% 39.89% 29.88%
Revenue growth, 5-year CAGR 49.77% 152.47% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALNY ASND Biotechnology median
Debt to equity 0.28 0.31 0.00
Current ratio 2.48 2.99 4.89
Net debt to EBITDA (3.41) (2.16) 1.01

Dividend

Metric ALNY ASND Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALNY ASND Biotechnology median
Market cap 20.98b 16.64b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack